Nuvation Bio Inc. insider trading
Every open-market purchase and sale by Nuvation Bio Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Nuvation Bio Inc.’s insiders pay?
From July 6, 2020 to June 11, 2026, 21 insiders reported 18 open-market purchases and 14 sales not made under a pre-set plan in Nuvation Bio Inc. Twelve months after each purchase was reported, the shares were −64.5% against the S&P 500 on average (median −62.2%), over 3 purchases with a full year of prices; 0% beat the index. After sales, the shares moved −63.1% against the index over 12 months (a negative figure means selling was the right call). That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on April 5, 2021 into $6,189 by November 2, 2026, −8.3% a year. It held shares 19% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $13,302 (+5.3% a year), and held throughout $20,033 (+13.3%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Liu Dongfang | CHIEF MEDICAL OFFICER | 0 | — | — | 4 | — | December 3, 2025 |
| Ecor1 Capital, LLC | CEO and Chairman of the Board | 2 | −69.2% (1) | 0% | 1 | −69.2% (1) | November 30, 2021 |
| Mashal Robert | Director | 3 | — | — | 0 | — | June 11, 2026 |
| Omega Fund V Gp Manager, Ltd. | 10% owner | 0 | — | — | 3 | −61.9% (3) | April 7, 2022 |
| Cui Xiangmin | Director | 2 | — | — | 0 | — | June 26, 2024 |
| Hung David | PRESIDENT AND CEO | 2 | — | — | 0 | — | June 18, 2025 |
| Bazemore Robert B | Director | 1 | −62.2% (1) | 0% | 0 | — | April 1, 2021 |
| Blickenstaff Kim D | Director | 1 | — | — | 0 | — | June 13, 2024 |
| Ecor1 Capital Fund Qualified, L.P. | Director | 1 | −62.1% (1) | 0% | 0 | — | April 13, 2021 |
| Falberg Kathryn E | Director | 1 | — | — | 0 | — | December 5, 2022 |
| Hanley David C. | CHIEF TECHNICAL OPERATIONS | 0 | — | — | 1 | — | November 21, 2025 |
| Hattersley Gary | CHIEF SCIENTIFIC OFFICER | 0 | — | — | 1 | — | November 24, 2025 |
| Markel Stacy | CHIEF PEOPLE OFFICER | 1 | — | — | 0 | — | June 18, 2025 |
| Nodelman Oleg | Director | 1 | — | — | 0 | — | September 21, 2023 |
| Omega Fund IV Gp, L.P. | 10% owner | 0 | — | — | 1 | −61.0% (1) | December 17, 2021 |
| Omega Fund V Gp, L.P. | 10% owner | 0 | — | — | 1 | −60.1% (1) | November 5, 2021 |
| Omega Fund V, L.P. | 10% owner | 0 | — | — | 1 | −65.7% (1) | December 9, 2021 |
| Sauvage Philippe | Chief Financial Officer | 1 | — | — | 0 | — | June 18, 2025 |
| Sjogren Colleen | Chief Commercial Officer | 1 | — | — | 0 | — | June 18, 2025 |
| Wang Junyuan Jerry | CEO, ANHEART THERAPEUTICS LTD. | 0 | — | — | 1 | — | November 13, 2024 |
| Wentworth Kerry | CHIEF REGULATORY OFFICER | 1 | — | — | 0 | — | June 18, 2025 |
When several insiders traded Nuvation Bio Inc.
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Nuvation Bio Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 1 buying crowd with six months of prices, it averaged −25.7% against the index. After 2 selling crowds, −44.1%. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| November 28, 2025 | 3 selling | −45.6% | −50.8% | not yet |
| December 31, 2021 | 4 selling | −30.9% | −37.4% | −57.7% |
| April 30, 2021 | 2 buying | −28.2% | −25.7% | −58.4% |